Working… Menu
Trial record 4 of 9 for:    amplyx

A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04804059
Recruitment Status : Completed
First Posted : March 18, 2021
Last Update Posted : March 18, 2021
Information provided by (Responsible Party):
Amplyx Pharmaceuticals

Brief Summary:
This is a single-center, open-label, non-randomized, single dose study in healthy male subjects. It was planned to enroll 2 cohorts of 5 subjects (10 subjects in total), with the target of achieving data in 4 evaluable subjects per cohort. Five subjects were to receive a single oral dose of APX001 and not more than (NMT) 3.1 megabecquerel (MBq) (84.0 microcurie [μCi]) 14C in the fed state. Five subjects were to receive a single IV administration containing APX001 and NMT 3.4 MBq (93.0 μCi) 14C in the fed state.

Condition or disease Intervention/treatment Phase
Fungal Infection Drug: [14C]-APX001 Oral Solution Drug: [14C]-APX001 Solution for Infusion Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-APX001 in Healthy Male Subjects After Oral and Intravenous Dosing
Actual Study Start Date : August 17, 2018
Actual Primary Completion Date : September 26, 2018
Actual Study Completion Date : September 26, 2018

Arm Intervention/treatment
Experimental: Cohort A
[14C]-APX001 Oral Solution
Drug: [14C]-APX001 Oral Solution
Total dose containing NMT 3.1 MBq (84.0 µCi) 14C

Experimental: Cohort B
[14C]-APX001 Solution for Infusion
Drug: [14C]-APX001 Solution for Infusion
Total dose containing NMT 3.4 MBq (93.0 µCi) 14C

Primary Outcome Measures :
  1. Mass balance recovery as measured by mass unit equiv/g after a single oral or single intravenous (IV) dose of carbon-14 (14C)-labelled APX001 ([14C]-APX001). [ Time Frame: 3 weeks ]
  2. Profiling of metabolites of [14C]-APX001 in plasma and excreta. [ Time Frame: 3 weeks ]
    Plasma, urine and feces samples from subjects dosed with [14C]-APX001 were analyzed using high resolution, accurate mass liquid chromatography tandem mass spectrometry (LC-MS/MS) with in-line fraction collection and off-line counting to obtain [14C]-radiochromatographic profiles and provide information on the nature of the radioactive components present, including chemical structure identification.

Secondary Outcome Measures :
  1. Elimination pathway of [14C]-APX001 following a single oral or single IV dose of [14C]-APX001. [ Time Frame: 3 weeks ]
    Amount of radioactivity recovered from urine and feces over time was measured by liquid scintillation counting (LSC) and expressed as a percentage of administered radioactivity.

  2. Extent of distribution of total radioactivity into blood cells following a single oral or single IV dose of [14C]-APX001. [ Time Frame: 3 weeks ]
    Amount of radioactivity in whole blood over time was quantified by LSC and expressed in ng equivalents free drug/g.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy males
  2. Aged 30 to 65 years of age
  3. Body mass index (BMI) of 18.0 to 32.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator
  4. Good state of health (mentally and physically) as indicated by a comprehensive clinical assessment (detailed medical history and a complete physical examination)
  5. Must have been willing and able to communicate and participate in the whole study
  6. Must have had regular bowel movements (i.e. average stool production of ≥1 and

    ≤3 stools per day)

  7. Must have provided written informed consent
  8. Must have adhered to the contraception requirements defined in Section 9.4 of the protocol (Appendix 16.1.1)

Exclusion Criteria:

  1. Subjects who had received any IMP in a clinical research study within the previous 3 months or a similar 14C radioactive clinical trial within the previous 12 months
  2. Subjects who were study site employees, or immediate family members of a study site or sponsor employee
  3. Subjects who had previously been enrolled in this study.
  4. History of any drug or alcohol abuse in the past 2 years
  5. Regular alcohol consumption in males >21 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
  6. Current smokers and those who had smoked within the last 12 months. A breath carbon monoxide (CO) reading of greater than 10 ppm at screening and admission
  7. Current users of e-cigarettes and nicotine replacement products and those who had used these products within the last 12 months
  8. Radiation exposure, including that from the present study, excluding background radiation but including diagnostic x-rays and other medical exposures, exceeded 5 millisieverts (mSv) in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 2017, was to participate in the study
  9. Subjects who did not have suitable veins for multiple venipunctures/cannulation as assessed by the investigator at screening
  10. Clinically significant abnormality on electrocardiogram (ECG) as judged by the investigator
  11. Clinically significant abnormal biochemistry, hematology or urinalysis at screening as judged by the investigator (laboratory parameters are listed in Appendix 1 of the protocol, Appendix 16.1.1)
  12. Positive drugs of abuse test result (drugs of abuse tests are listed in Appendix 1 of the protocol, Appendix 16.1.1)
  13. Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
  14. Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <80 mL/min using the Cockcroft-Gault equation
  15. History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal (GI) disease, neurological or psychiatric disorder, as judged by the investigator
  16. Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
  17. Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever was allowed unless it was active
  18. Donation or loss of greater than 400 mL of blood within the previous 3 months
  19. Subjects who were taking, or had taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies in the 14 days before IMP administration (see Section 11.4 of the protocol, Appendix 16.1.1). Exceptions may have applied on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor.
  20. Failure to satisfy the investigator of fitness to participate for any other reason

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04804059

Layout table for location information
United Kingdom
Quotient Sciences
Ruddington, Nottingham, United Kingdom, NG11 6JS
Sponsors and Collaborators
Amplyx Pharmaceuticals
Layout table for additonal information
Responsible Party: Amplyx Pharmaceuticals Identifier: NCT04804059    
Other Study ID Numbers: APX001-104
First Posted: March 18, 2021    Key Record Dates
Last Update Posted: March 18, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pharmaceutical Solutions